EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Hotaka Maruyama iD, Eiko Iwasa iD, Shinya Watanabe iD, Tomoaki Hasegawa iD, Kazuhiro Kajiyama iD, Taihei Tanaka

Clinical Pharmacology & Therapeutics · 2026-03 · 119 (3) · 721-728

DOI: 10.1002/cpt.70142 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 21.11.2025. Verfasst von Hotaka Maruyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Hauptthemen laut MEDLINE: Teriparatide, Cardiovascular Diseases, Antibodies, Monoclonal, Bone Density Conservation Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal. This study aimed to compare the cardiovascular risks of romosozumab with those of teriparatide in the overall population and in groups with a history of major adverse cardiovascular events (MACE). A new user cohort study was conducted using Japan’s national claims database. Patients aged ≥ 40 years who initiated romosozumab or teriparatide between March 2019 and March 2023 were analyzed. A multivariable Cox proportional hazards model was used to estimate the adjusted hazard ratio (aHR) for MACE. Subgroup analyses were conducted based on MACE history. A total of 251,219 romosozumab and 500,445 teriparatide users were analyzed (most common age group was 80–89 years for both drugs; men: 9.33% for romosozumab and 14.14% for teriparatide). MACE occurred in 1853 romosozumab and 3427 teriparatide users, with incidence rates of 1.09 and 1.22 per 100 person‐years, respectively. The aHR (95% confidence interval [CI]) for romosozumab compared with teriparatide was 1.00 (0.94–1.06). In subgroup analyses based on MACE history, the aHRs (95% CI) for no history, for the one‐year period leading up to t 0 , and for more than 1 year before t 0 were 1.01 (0.95–1.08), 0.93 (0.72–1.21), and 1.00 (0.85–1.18), respectively. In conclusion, no statistically significant difference in MACE risk was observed between romosozumab and teriparatide in Japan’s national claims database, regardless of MACE history.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeriparatideCardiovascular DiseasesAntibodies, MonoclonalBone Density Conservation AgentsHumansMaleFemaleJapanAgedMiddle AgedAged, 80 and overDatabases, FactualAdultCohort StudiesIncidenceRisk Assessment

Substanzen

TeriparatideromosozumabAntibodies, MonoclonalBone Density Conservation Agents

Autor:innen und Institutionen

  • Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Regulatory Science Research, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

ORCID-Profile: Hotaka Maruyama, Eiko Iwasa, Shinya Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama

Zitieren

APA

Maruyama, H., Iwasa, E., Watanabe, S., Hasegawa, T., Kajiyama, K., & Tanaka, T. (2026). Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database. Clinical Pharmacology & Therapeutics, 119(3), 721-728. https://doi.org/10.1002/cpt.70142

Vancouver

Maruyama H, Iwasa E, Watanabe S, Hasegawa T, Kajiyama K, Tanaka T. Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database. Clinical Pharmacology & Therapeutics. 2026;119(3):721-728. doi:10.1002/cpt.70142

BibTeX
@article{Maruyama2026,
  author = {Maruyama, Hotaka and Iwasa, Eiko and Watanabe, Shinya and Hasegawa, Tomoaki and Kajiyama, Kazuhiro and Tanaka, Taihei},
  title = {Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {3},
  pages = {721--728},
  doi = {10.1002/cpt.70142}
}
Kostenlos starten →